Andrew Lewis
MD PhD FRCP FESC
Principal Investigator
- BHF Intermediate Clinical Research Fellow; Radcliffe Department of Medicine
- Consultant Cardiologist (Honorary); Oxford Heart Centre
- Kemp Postdoctoral Fellow; Lincoln College Oxford
- EDI Champion; Oxford Centre for Clinical Magnetic Resonance Research
Spatial cardiology
Our group develops and applies advanced imaging techniques across various spatial scales, from subcellular to whole-heart, to better understand cardiovascular disease mechanisms, identify new therapeutic targets, and enhance early detection of treatment effects in experimental medicine trials. By integrating human cells, tissue samples, and non-invasive imaging of research and trial participants and patients, we aim to maximise the translational potential and mechanistic insights of our work. Current projects focus on metabolic and immunological pathways in heart failure, exploiting state-of-the-art spatial profiling techniques. We collaborate with a broad network of local, national, and international partners across academia and industry, and we welcome applicants with interdisciplinary expertise – please reach out to discuss current opportunities.
Andrew undertook doctoral research in translational cardiovascular imaging in the group of Professor Stefan Neubauer in Oxford. He was then appointed as a Clinical Lecturer in Oxford, prior to a post-doctoral fellowship at Massachusetts General Hospital in the laboratory of Professor Matthias Nahrendorf. Following award of a BHF Intermediate Clinical Fellowship, he was appointed as a Principal Investigator and Group Leader at the Radcliffe Department of Medicine and the Oxford BHF Centre for Research Excellence as well as Honorary Consultant Cardiologist at the Oxford Heart Centre. Andrew is a Fellow of the Royal College of Physicians of London, and the Kemp Postdoctoral Fellow at Lincoln College Oxford.
Recent publications
-
Sex-specific cardiometabolic multimorbidity, metabolic syndrome and left ventricular function in heart failure with preserved ejection fraction in the UK Biobank.
Journal article
Bertrand A. et al, (2025), Cardiovasc Diabetol, 24
-
Regression of late gadolinium enhancement in a case of eosinophilic granulomatous polyangiitis with cardiac involvement.
Journal article
Tang P-T. et al, (2025), Eur Heart J Cardiovasc Imaging
-
MicroRNA-210 Enhances Cell Survival and Paracrine Potential for Cardiac Cell Therapy While Targeting Mitophagy.
Journal article
Alonaizan R. et al, (2025), J Funct Biomater, 16
-
Metabolic flexibility and reverse remodelling of the failing human heart.
Journal article
Green PG. et al, (2025), Eur Heart J
-
Correction: Multi-modal characterisation of early-stage, subclinical cardiac deterioration in patients with type 2 diabetes.
Journal article
Bertrand A. et al, (2025), Cardiovasc Diabetol, 24